Related Experiment Video
Updated: Sep 15, 2025
05:39
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
960
Radiosensitizers in Cancer Therapy: A Global Bibliometric Analysis
Shreyas Annagiri1, Paul M Harary1, Yusuke S Hori1
1Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA.
Biorxiv : the Preprint Server for Biology
|July 16, 2025
Summary
This bibliometric analysis reveals global trends in radiosensitizer research. Breast cancer studies show rapid growth, with the US, China, and Germany leading in publications on agents like ATM kinase inhibitors and gold nanoparticles.
Area of Science:
- Oncology
- Radiotherapy
- Pharmacology
Background:
- Radiosensitizers enhance radiotherapy's cancer-killing effect while protecting healthy tissues.
- Research encompasses diverse therapeutic agents for radiosensitization.
- Investigating international development trends is crucial for advancing cancer treatment.
Purpose of the Study:
- To analyze global trends in radiosensitizer research from 1956 to 2024.
- To identify leading countries, author impacts, and collaborative patterns.
- To map evolving research themes and keywords in radiosensitizer development.
Main Methods:
- Bibliometric analysis of 12,690 publications (1956-2024).
- Evaluation of author contributions, country productivity, and international collaborations.
- Analysis of research themes, keywords, and publication growth rates by cancer type.
Main Results:
- The United States, China, and Germany are leading countries in radiosensitizer research.
- Breast cancer radiosensitizer studies exhibit the highest annual growth rate.
- Commonly investigated radiosensitizers include ATM kinase inhibitors, chemotherapies, gold nanoparticles, mTOR inhibitors, natural compounds, and PARP inhibitors.
Conclusions:
- China shows the most significant increase in annual publication rates.
- Pre-clinical research focuses on gold nanoparticles and targeted therapies.
- Clinical studies prioritize radiosensitizing chemotherapies.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:21Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K